Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$148.75
-0.5%
$155.83
$143.13
$175.97
$358.45B0.537.33 million shs5.86 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$4.15
-1.0%
$4.71
$3.53
$11.36
$580.79M1.597.48 million shs1.71 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.27
-0.2%
$27.07
$25.23
$40.37
$148.75B0.6141.75 million shs15.34 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.30%+3.54%-3.65%-5.92%-8.63%
Novavax, Inc. stock logo
NVAX
Novavax
+2.95%+5.01%-10.85%+3.46%-48.14%
Pfizer Inc. stock logo
PFE
Pfizer
+0.23%+2.45%-3.80%-7.09%-34.05%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.9067 of 5 stars
3.23.04.23.93.02.51.9
Novavax, Inc. stock logo
NVAX
Novavax
3.8217 of 5 stars
3.53.00.04.71.40.80.6
Pfizer Inc. stock logo
PFE
Pfizer
4.995 of 5 stars
3.25.04.24.83.11.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.46
Hold$175.8618.22% Upside
Novavax, Inc. stock logo
NVAX
Novavax
3.00
Buy$17.00309.64% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.3338.31% Upside

Current Analyst Ratings

Latest PFE, NVAX, and JNJ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$169.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$168.00 ➝ $167.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$180.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$181.00 ➝ $175.00
4/15/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/22/2024
Pfizer Inc. stock logo
PFE
Pfizer
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/13/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00
3/1/2024
Novavax, Inc. stock logo
NVAX
Novavax
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$35.00 ➝ $19.00
3/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$85.16B4.21$13.63 per share10.91$28.57 per share5.21
Novavax, Inc. stock logo
NVAX
Novavax
$983.71M0.59N/AN/A($6.04) per share-0.69
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.54$2.98 per share8.82$15.81 per share1.66

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$35.15B$16.049.2713.582.4645.26%36.43%15.01%7/18/2024 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$545.06M-$5.53N/AN/AN/A-55.41%N/A-32.63%5/14/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3672.979.481.183.62%10.88%4.91%5/1/2024 (Confirmed)

Latest PFE, NVAX, and JNJ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
4/16/2024Q1 24
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.64$2.71+$0.07$3.22$21.39 billion$21.38 billion    
2/28/2024Q4 2023
Novavax, Inc. stock logo
NVAX
Novavax
-$0.49-$1.44-$0.95-$1.44$310.96 million$291.34 million      
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.763.20%+5.70%29.68%63 Years
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.40%+2.57%466.67%15 Years

Latest PFE, NVAX, and JNJ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.243.36%5/20/20245/21/20246/4/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.38
1.16
0.91
Novavax, Inc. stock logo
NVAX
Novavax
N/A
0.70
0.67
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Novavax, Inc. stock logo
NVAX
Novavax
0.90%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
131,9002.41 billion2.41 billionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,543139.95 million138.69 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

PFE, NVAX, and JNJ Headlines

SourceHeadline
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
zacks.com - April 24 at 1:06 PM
Pfizer Inc. (NYSE:PFE) Shares Sold by Community Bank & Trust Waco TexasPfizer Inc. (NYSE:PFE) Shares Sold by Community Bank & Trust Waco Texas
marketbeat.com - April 24 at 12:07 PM
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
zacks.com - April 24 at 11:06 AM
Pfizer gets grant for treatment of cancer using engineered immune cells targeting bcmaPfizer gets grant for treatment of cancer using engineered immune cells targeting bcma
pharmaceutical-technology.com - April 24 at 10:09 AM
6 of the Highest-Yielding S&P 500 Stocks Offer Huge Passive Income6 of the Highest-Yielding S&P 500 Stocks Offer Huge Passive Income
247wallst.com - April 24 at 7:30 AM
The Top 7 Dividend Stocks to Buy in 2024 to Build Lasting WealthThe Top 7 Dividend Stocks to Buy in 2024 to Build Lasting Wealth
investorplace.com - April 24 at 7:25 AM
Pfizer (PFE) Scheduled to Post Quarterly Earnings on WednesdayPfizer (PFE) Scheduled to Post Quarterly Earnings on Wednesday
americanbankingnews.com - April 24 at 1:58 AM
Pfizer’s Emblaveo receives European marketing approval for patients with multidrug-resistant infections and limited treatment optionsPfizer’s Emblaveo receives European marketing approval for patients with multidrug-resistant infections and limited treatment options
pharmabiz.com - April 24 at 12:08 AM
Pfizer confirms end of Boulder R&D operationsPfizer confirms end of Boulder R&D operations
msn.com - April 24 at 12:08 AM
Pfizer Inc. (NYSE:PFE) Shares Bought by South Dakota Investment CouncilPfizer Inc. (NYSE:PFE) Shares Bought by South Dakota Investment Council
marketbeat.com - April 23 at 8:58 PM
Pfizer to shutter Boulder R&D operationsPfizer to shutter Boulder R&D operations
bizwest.com - April 23 at 7:07 PM
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
investorplace.com - April 23 at 3:00 PM
Pfizer (NYSE:PFE) Shares Up 0.5%Pfizer (NYSE:PFE) Shares Up 0.5%
marketbeat.com - April 23 at 2:58 PM
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (ADUS), Pfizer (PFE) and Cardinal Health (CAH)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (ADUS), Pfizer (PFE) and Cardinal Health (CAH)
markets.businessinsider.com - April 23 at 2:03 PM
Better Buy: Pfizer vs. Viking TherapeuticsBetter Buy: Pfizer vs. Viking Therapeutics
fool.com - April 23 at 9:15 AM
Pfizer vs Moderna battle over COVID vaccine patents begins in UKPfizer vs Moderna battle over COVID vaccine patents begins in UK
finance.yahoo.com - April 23 at 7:37 AM
Pfizer vs Moderna battle over COVID vaccine patents begins in UKPfizer vs Moderna battle over COVID vaccine patents begins in UK
reuters.com - April 23 at 7:21 AM
New York State Common Retirement Fund Has $281.24 Million Position in Pfizer Inc. (NYSE:PFE)New York State Common Retirement Fund Has $281.24 Million Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 22 at 9:33 PM
Pfizer (PFE) Rises Higher Than Market: Key FactsPfizer (PFE) Rises Higher Than Market: Key Facts
zacks.com - April 22 at 6:51 PM
3 Blue-Chip Stocks That Will Beat Index Returns Over the Next 3 Years3 Blue-Chip Stocks That Will Beat Index Returns Over the Next 3 Years
investorplace.com - April 22 at 5:44 PM
EC approval for Pfizer’s Emblaveo in multidrug-resistant infectionsEC approval for Pfizer’s Emblaveo in multidrug-resistant infections
thepharmaletter.com - April 22 at 3:24 PM
Pfizers Emblaveo Gets EU Marketing Authorization For Serious Infectious DiseasePfizer's Emblaveo Gets EU Marketing Authorization For Serious Infectious Disease
markets.businessinsider.com - April 22 at 3:24 PM
EU regulators approve Pfizer antibiotic EmblaveoEU regulators approve Pfizer antibiotic Emblaveo
seekingalpha.com - April 22 at 3:24 PM
Pfizer (NYSE:PFE) Stock Price Up 1.1%Pfizer (NYSE:PFE) Stock Price Up 1.1%
marketbeat.com - April 22 at 1:55 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Novavax logo

Novavax

NASDAQ:NVAX
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.